AB Science AB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
AB Science will hold a web conference on Wednesday, October 14, 2026, from 6:00 p.m. to 7:30 p.m.
-
AB Science today reports its revenues for the first half of 2026 and provides an update on its activities
-
AB Science provides an update on its development plan and financial calendar following a sponsor Good Clinical Practice inspection
Trading Information
- Previous Close Price
- €0.54
- Day Range
- €0.53–0.54
- 52-Week Range
- €0.50–1.61
- Bid/Ask
- €0.54 / €0.54
- Shares Outstanding
- 96.53M
- Market Cap
- €52.03M
- Volume/Avg
- 85,207 / 366,992
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 30.85
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
AB Science is a clinical-stage pharmaceutical company that has developed a diversified portfolio of medicines targeting unmet medical needs, based on two platforms. Masitinib platform: It is based on masitinib, a selective protein kinase inhibitor in development for neurodegenerative diseases, oncology, & inflammatory diseases. It has the clinical development of masitinib in neurodegenerative diseases (specifically Alzheimer's disease, amyotrophic lateral sclerosis, & progressive forms of multiple sclerosis). ALDH/Microtubule Platform: It is a portfolio of synthetic agents that target cancer cells by destabilising microtubules, which are essential for cell division & cancer stem cells, by inhibiting enzymes that are essential for maintaining their physiological state & survival.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Growth
- Total Number of Employees
- 33
- Website
- https://www.ab-science.com
Valuation
|
Metric
|
AB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 30.85 |
Price/Cash Flow | — |
Price/Earnings
AB
Financial Strength
|
Metric
|
AB
|
|---|---|
Quick Ratio | 0.78 |
Current Ratio | 0.85 |
Interest Coverage | −4.38 |
Quick Ratio
AB
Profitability
|
Metric
|
AB
|
|---|---|
Return on Assets (Normalized) | −35.49% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
AB
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|>Ww&NS> | LOCK|?f?<S | $73B | |||
| Teva Pharmaceutical Industries Ltd
TEVA
| LOCK|>$^lkL! | LOCK|>y?R^ | $49B | |||
| Haleon PLC ADR
HLN
| LOCK|$nl?S^ | LOCK|vG< | $38B | |||
| Zoetis Inc Class A
ZTS
| LOCK|$@b@Zzy | LOCK|wTd | $34B | |||
| Viatris Inc
VTRS
| LOCK|$?yNlH@ | LOCK|<G | $21B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|%@ | LOCK|@p | $12B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|b@<zNyP | LOCK|#!t | $12B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|hr&<sW | LOCK|?^r | $6B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|k!!yqg> | LOCK|>$V&s | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|zwL??h | LOCK|<w | $2B |
United States